

# SOPs CLEAR AND SIMPLE FOR HEALTHCARE MANUFACTURERS



Susan Schniepp, Brian Matye,  
and Jeanne Moldenhauer

# **SOPs Clear and Simple**

## **For Healthcare Manufacturers**

Susan Schniepp  
Brian Matye  
Jeanne Moldenhauer

To order this book, please visit: [go.pda.org/SOPS](http://go.pda.org/SOPS)

PDA  
Bethesda, MD, USA  
DHI Publishing, LLC  
River Grove, IL, USA

[www.pda.org/bookstore](http://www.pda.org/bookstore)

10 9 8 7 6 5 4 3 2 1

**ISBN: 978-1-942911-33-3**

**Copyright © 2018 Susan Schniepp, Brian Matye and Jeanne Moldenhauer**  
**All rights reserved.**

All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system or transmitted in any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America.

Where a product trademark, registration mark, or other protected mark is made in the text, ownership of the mark remains with the lawful owner of the mark. No claim, intentional or otherwise, is made by reference to any such marks in the book. Websites cited are current at the time of publication. The authors have made every effort to provide accurate citations. If there are any omissions, please contact the publisher.

While every effort has been made by the publisher and the authors to ensure the accuracy of the information expressed in this book, the organization accepts no responsibility for errors or omissions. The views expressed in this book are those of the authors and may not represent those of either Davis Healthcare International or the PDA, its officers, or directors.



*Connecting People, Science and Regulation®*



This book is printed on sustainable resource paper approved by the Forest Stewardship Council. The printer, Gasch Printing, is a member of the Green Press Initiative and all paper used is from SFI (Sustainable Forest Initiative) certified mills.

**PDA Global Headquarters**

Bethesda Towers, Suite 600  
4350 East-West Highway  
Bethesda, MD 20814  
United States  
[www.pda.org/bookstore](http://www.pda.org/bookstore)  
001-301-986-0293

**Davis Healthcare International Publishing, LLC**

2636 West Street  
River Grove  
IL 60171  
United States  
[www.DHIBooks.com](http://www.DHIBooks.com)

[www.pda.org/bookstore](http://www.pda.org/bookstore)

---

---

# CONTENTS

## **Preface**

**vii**

<b>I</b>	<b>INTRODUCTION: WHAT IS AN SOP AND WHY DO WE WRITE THEM?</b>	<b>I</b>
	Definition: Standard Operating Procedure	I
	SOPs Provide Benefits for your Organization	6
	References	7
<b>2</b>	<b>REGULATORY REQUIREMENTS FOR SOPs</b>	<b>9</b>
	Introduction	9
	Requirements Stated in the FDA GMPs for Drug Products	12
	FDA GMPs for Medical Devices	21
	FDA Requirements for Biological Products	21
	Eudralex GMPs for the European Union	24
	Eudralex – The Rules Governing Medicinal Products in the European Union	44
	World Health Organization (WHO)	68
	Data Integrity Requirements	92
	FDA Guidance on Data Integrity	92

**iii**

	Medicines Health and Regulatory Agency Guidance on Data Integrity	93
	The European Union's Data Protection Regulation (GDPR) Requirements	94
	Determining the SOPs You Need	98
	Putting It All Together	101
	References	102
<b>3</b>	<b>DEFINING THE REQUIREMENTS OF SOPs</b>	<b>105</b>
	Example SOP formats	110
<b>4</b>	<b>SEVEN ESSENTIAL ELEMENTS OF SOPs</b>	<b>117</b>
	Element 1: Unique Identifier and Title	128
	Element 2: Issue Date and Effective Date	119
	Element 3: Purpose and Scope	120
	Element 4: Roles and Responsibilities	122
	Element 5: Change History	123
	Element 6: Official Signatures	124
	Element 7: Step-by-Step Instructions	124
	Element 8: Acceptance Criteria (If Applicable)	125
	Additional SOP Sections	126
	The Level of Complexity in SOPs	127
	Wrapping Up	130
	References	130
<b>5</b>	<b>AVOIDING PITFALLS IN SOPs</b>	<b>131</b>
	Pitfall #1: Providing Too Much Information	132
	Pitfall #2: Providing Too Little Information	133
	Pitfall #3: Providing Unneeded Specific Information	133
	Pitfall #4: Providing Ambiguous Information	134
	Pitfall #5: SOPs Not Accessible	134
	Pitfall #6: Allowing Access to Obsolete SOPs	134
	Pitfall #7: Unnecessary SOPs	135
	Pitfall #8: Poor Data Integrity Instructions	135
<b>6</b>	<b>ADDITIONAL CONSIDERATIONS FOR SOPs</b>	<b>137</b>
	Types of Changes	139
	Dealing With Change	140

<b>ADDENDUM 1 FREQUENTLY ASKED QUESTIONS</b>	<b>141</b>
<b>ADDENDUM 2 EXAMPLE SOP TEMPLATE</b>	<b>145</b>
<b>ADDENDUM 3 EXAMPLE SOP DEVELOPMENT AND REVIEW PROCESS</b>	<b>149</b>
<b>ADDENDUM 4 EXAMPLE PROCESS FLOW DIAGRAM</b>	<b>153</b>
<b>ABOUT THE AUTHORS</b>	<b>157</b>
<b>BIBLIOGRAPHY</b>	<b>159</b>
<b>GLOSSARY</b>	<b>161</b>



---

---

## PREFACE

There are four simple sentences that define the concept of compliance and its relationship to SOPs: Say what you do. Do what you say. Prove it. Improve it. Companies usually use their SOPs to show that they have control over their processes, thereby demonstrating compliance to regulatory expectations. “Say what you do,” relates directly to the written SOP defining the steps taken to fulfill regulatory requirements for compliance. “Do what you say” equates to following the SOP. This concept seems simple enough yet the number one topic of 483 observations for biologics, drugs and devices from 2013 through 2016 included failure to follow SOPs, procedures not in writing and lack of adequate procedures. This trend is disappointing because there are numerous webinars, seminars and workshops designed to train personnel in writing and following SOPs. In addition, there are a myriad of articles, books and manuals discussing the who, what, when, where and how of SOPs. If that isn’t enough, there are several experienced consultants who companies can hire to help write, review and critique their SOPs.



This book was written to offer some practical advice to the pharmaceutical, biotechnology and medical device industries so they may better understand why they need SOPs, how to write them and what should be included in them. It is a simple, straightforward approach to writing SOPs and highlighting their importance in maintaining compliant operations critical to manufacturing quality products.

Susan Schniepp  
Distinguished Fellow  
Regulatory Compliance Associates Inc.

Brian Matye  
Chief Executive Officer  
Regulatory Compliance Associates Inc.

Jeanne Moldenhauer  
Vice-President  
Excellent Pharma Consulting, Inc.